Cerity Partners
RANI icon

Cerity Partners’s Rani Therapeutics RANI Stock Holding History

Cerity Partners’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.5K Hold
19,090
– – ﹤0.01% 3378
2026
Q1 		$14K Buy
19,090
+9,090
+91% +$11.6K ﹤0.01% 3194
2025
Q4 		$13.5K Hold
10,000
– – ﹤0.01% 2853
2025
Q3 		$5K Hold
10,000
– – ﹤0.01% 2738
2025
Q2 		$5.14K Hold
10,000
– – ﹤0.01% 2626
2025
Q1 		$12.6K Hold
10,000
– – ﹤0.01% 2459
2024
Q4 		$13.7K Hold
10,000
– – ﹤0.01% 2409
2024
Q3 		$21.6K Buy
+10,000
New +$28.7K ﹤0.01% 2509

Other funds holding RANI

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Cerity Partners's RANI Position: Q2 2026 in Review

Cerity Partners held its Rani Therapeutics (RANI) position steady in Q2 2026 at 19,090 shares worth $14.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3378.

Cerity Partners first reported a position in RANI in Q3 2024 and has held it in 8 quarters since. The position peaked at $21.6K in Q3 2024. 68 funds tracked by Wall St. Rank hold RANI as of Q2 2026.

  • Cerity Partners held 19,090 shares of Rani Therapeutics worth $14.5K as of Q2 2026.
  • Cerity Partners left its Rani Therapeutics share count unchanged in Q2 2026.
  • Rani Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #3378 holding.
  • Cerity Partners first reported a position in Rani Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Cerity Partners's Rani Therapeutics position peaked at $21.6K in Q3 2024.
  • 68 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.